Bugworks is a startup based in India. Brouky records 1 investor associated with the company.
Bugworks develops antibiotic discovery technologies to overcome efflux-mediated drug resistance and enable entry of antibiotics into Gram-negative pathogens. The company has generated multiple novel antibacterial chemical series that it reports are now at clinical stages and is a recipient of CARB-X funding.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.